molecules have emerged in the last few decades.
However, this has met with limited success owing to extensive molecular diversity that spans genetic and epigenetic alterations. The advent of genomic and proteomic technologies provide a comprehensive perspective of the disease; revealing a host of unique attributes including somatic and inherited mutations, polymorphisms, gene expression, amplification or copy number variations, and protein over-expression, loss, mutations and copy number variations.Interpreting this deluge of information is challenging both in terms of data management and retrieval. It is in this regard that databases catering exclusively to dissemination of cancer associated data that would assist efforts aimed at testing new chemotherapy treatments have emerged recently [2] . However, there have been few efforts at collecting and compiling valuable information to manage drug resistance data, especially the ones that are based on specific mutations in drug targets. rep01445/full/srep01445.html). The clustering module in the database allows the user to cluster mutants of a drug target to understand similarity among targets obtained from different sources or cell lines.These clusters are based on sequence similarity and represented via a visual alignment tree of wild type sequences of each target with their mutants. This feature helps users to view the distance of different mutant sequences in the alignment against selected targets in CancerDR. The authors also provide a comprehensive list of effective anti-cancer drugs against various tissue types obtained by clustering module, which is a valuable resource for the community.
One of the major aims of the database is to provide the users with a comprehensive understanding of the effect of mutations in drug targets on acquired drug resistance. The integrated NGS mapping tool allows users to map short reads, contigs and sequences on drug targets. This is particularly useful to detect mutations in drug targets of defined patient subsets, based on which, one can identify anti-cancer drugs for those patients. Since mutations in drug targets are known to cause structural changes that in turn are responsible for acquired drug resistance, the database has an in-built repository of predicted tertiary structures of all the drug targets, and their mutants/variants. This allows rapid identification of structural deviation due to individual mutations. As an extension of this tool, the database also allows users to predict and compare structures for userdefined protein sequences with preexisting protein structures available in CancerDR.
The authors claim that the database would allow extension of the concept of personalized medicine in cancer treatment by allowing users to select best therapeutic options for a particular cancer type. A major shortcoming of the CancerDR database is its exclusive cancer cell line based content. Having access to information about how different cancer cell lines respond to different chemotherapy treatments will no doubt assist scientists and physicians to suggest the best drug options for patients. However, in practice, this conceptual extension based on information derived from cancer cell lines has received mixed reactions. A recent commentary has emphasized that cell line data is only the first step in bringing new treatments into the clinic [3] . It states that even large numbers of cell lines cannot predict how immune mechanisms and the tumor microenvironment will factor into a drug's effectiveness, which renders wide-sweeping conjectures based on cell lines extremely unreliable. That being said, the authors do acknowledge the deficiency and outline the necessity to integrate cancer patient data into their database. However, drug resistance information on cells lines from the database can be applied to explore new mechanisms that could be relevant in improving drug delivery and distribution.
In my own experience, CancerDR is a very valuable resource for the cancer research community and would definitely advance molecular and pharmacological research in the area. The tools are extremely user friendly and the format of data output makes analysis very intuitive. The authors allow/invite contributions from the community which makes the database very dynamic in terms of content. In summation, CancerDR is a valuable resource and offers a compilation of valuable scientific information while providing a free accessible platform with user-friendly tools.
